Meeting
2014 ASCO Annual Meeting
Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 vg in patients with melanoma.
Authors
Rachel Lubong Sabado
Icahn School of Medicine at Mount Sinai, New York, NY
Rachel Lubong Sabado , Anna C. Pavlick , Sacha Gnjatic , Patrick Alexander Ott , Farah Hasan , Meredith Spadaccia , Isabelita Vengco , Rose Marie Holman , Caroline Muren , Crystal Escano , Ethel Yepes , Claire Stein , Achim A Jungbluth , Linda S. Pan , Ralph Rudolph Venhaus , Nina Bhardwaj
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT01079741
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS9119)
DOI
10.1200/jco.2014.32.15_suppl.tps9119
Abstract #
TPS9119
Poster Bd #
314B
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Retrospective cohort analysis of adjuvant NY-ESO-1 vaccines in stage III melanoma.
First Author: Michael William Lattanzi
Poster
2016 ASCO Annual Meeting
A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand.
First Author: Nina Bhardwaj
Poster
2016 ASCO Annual Meeting
Autologous genetically engineered NY-ESO-1c259T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing tumors.
First Author: Crystal Mackall
Poster
2015 ASCO Annual Meeting
Phase I study of safety and immunogenicity of ADU-623, a live-attenuated Listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRvIII and NY-ESO-1, in patients with WHO grade III/IV astrocytomas.
First Author: Marka Crittenden